tbuckley/cabot-search huggingface dataset:
Preventing tumor progression to the bone by induced tumor-suppressing MSCs
Authors: Xun Sun, Kexin Li, Rongrong Zha, Shengzhi Liu, Yao Fan, Di Wu, Misato Hase, Uma K. Aryal, Chien-Chi Lin, Bai-Yan Li, Hiroki Yokota
Journal: Theranostics (2021)

Background: Advanced breast cancer metastasizes to many organs including bone, but few effective treatments are available.Here we report that induced tumor-suppressing (iTS) MSCs protected bone from metastases while un-induced MSCs did not.Methods: iTS MSCs were generated by overexpressing Lrp5, β-catenin, Snail, or Akt.Their tumorsuppressing capability was tested using a mouse model of mammary tumors and bone metastasis, human breast cancer tissues and cancer cell lines.Results: In a mouse model, the induced MSC-derived conditioned medium (MSC CM) reduced mammary tumors and suppressed tumor-induced osteolysis.Tumor-promoting genes such as CXCL2 and LIF, as well as PDL1, a blocker of T-cell-based immune responses were downregulated.Proteomics analysis revealed that heat shock protein 90 (Hsp90ab1), calreticulin (Calr) and peptidylprolyl isomerase B (Ppib), which are highly expressed intracellular proteins in many cancers, were enriched in MSC CM as atypical tumor suppressors.Thus, overexpressing selected genes that were otherwise tumorigenic rendered MSCs the tumor-suppressing capability through the atypical suppressors, as well as p53 and Trail.Notably, the inhibitory effect of Lrp5-and Akt-overexpressing MSC CMs, Hsp90ab1 and Calr presented selective inhibition to tumor cells than non-tumor cells.The development of bone-resorbing osteoclasts was also suppressed by MSC CMs.Conclusion: Collectively, the results showed an anti-tumor effect of iTS MSCs and suggested novel therapeutic approaches to suppress the progression of tumors into the bone.
Microglia‐derived galectin‐3 in neuroinflammation; a bittersweet ligand?
Authors: Reza Rahimian, Louis‐Charles Béland, Sachiko Sato, Jasna Kriz
Journal: Medicinal Research Reviews (2021)

Galectins are soluble β-galactoside-binding proteins found in all multicellular organisms. Galectins may act as danger-associated molecular patterns in innate immunity and/or as pattern-recognition receptors that bind to pathogen-associated molecular patterns. Among different galectin family members, galectin-3 has been the focus of studies in neurodegenerative diseases in recent years. This lectin modulates brain innate immune responses, microglia activation patterns in physiological and pathophysiological settings in a context-dependent manner. Galectin-3 is considered as a pivotal tuner of macrophage and microglial activity. Indeed galectin-3 acts as a double edged sword in neuroinflammatory context and this multimodal lectin has diverse roles in physiological and pathophysiological conditions. Better understanding of galectin-3 physiology (its extracellular and intracellular actions) and structure (its C terminus vs. N terminus) is instrumental to design molecules that selectively modulate galectin-3 function toward neuroprotective phenotypes. Several experimental studies using different approaches and methods have demonstrated both protective and deleterious effects of galectin-3 in neuroinflammatory diseases. According to the crucial role of galectin-3 in modulation of innate immune response in brain, it is an attractive target in drug discovery of neurodegenerative diseases. The current insight attempts to provide an updated and balanced discussion on the role of galectin-3 as a complex endogenous immune modulator. This helps to have a better insight into the development of galectin-3 modulators with translational value in different neurological disorders including stroke and neurodegenerative diseases, such as Alzheimer's disease, Huntington's disease and Parkinson's disease.
The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients
Authors: Elisa Teyssou, Cathia Soulie, Benoit Visseaux, Sidonie Lambert-Niclot, Valentine Ferre, Stéphane Marot, Aude Jary, Sophie Sayon, Karen Zafilaza, Valentin Leducq, Aurélie Schnuriger, Basma Abdi, Marc Wirden, Nadhira Houhou-Fidouh, Charlotte Charpentier, Laurence Morand-Joubert, Sonia Burrel, Diane Descamps, Vincent Calvez, Anne Geneviève Marcelin
Journal: Journal of Infection (2021)
Abstract 13336: Placental Oxygenation in Fetuses With and Without a Heart Defect
Authors: Camilla Omann, Mette Lauridsen, Steffen Ringgaard, Zarmiga Karunanithi, Vibeke Hjortdal
Journal: Circulation (2019)

Introduction: Placental infarctions, compromised placental growth, and placental dysfunction in terms of preeclampsia have been demonstrated in pregnancies with fetal heart defects. Blood oxygen le...
Fasting-induced FOXO4 blunts human CD4+ T helper cell responsiveness
Authors: Kim Han, Komudi Singh, Matthew J. Rodman, Shahin Hassanzadeh, Kaiyuan Wu, An Nguyen, Rebecca D. Huffstutler, Fayaz Seifuddin, Pradeep K. Dagur, Ankit Saxena, J. Philip McCoy, Jinguo Chen, Angélique Biancotto, Katherine E. R. Stagliano, Heather L. Teague, Nehal N. Mehta, Mehdi Pirooznia, Michael N. Sack
Journal: Nature Metabolism (2021)
P23.03 The New Therapy on Esophageal Leiomyosarcoma in the Upper Esophagus
Authors: Z. Zhai, L. Jiang, Y. Ye, X. Li, G. Lan, H. Chen, L. Huang, Y. Zhu, K. Du, W. Wang, C. Xu
Journal: Journal of Thoracic Oncology (2021)
Abstract P22: A high-throughput anti-SARS-CoV-2 IgG testing platform for COVID-19
Authors: Jinwei Du, Eric Chu, Dayu Zhang, Chuanyi M. Lu, Aiguo Zhang, Michael Sha
Journal: Clinical Cancer Research (2021)

Abstract Background: Serology tests for detecting the antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can identify previous infection and help to confirm the presence of current infection. Objective: The aim of this study was to evaluate the performances of a newly developed high throughput immunoassay for anti-SARS-CoV-2 IgG antibody detection. Results: Clinical agreement studies were performed in 77 COVID-19 patient serum samples and 226 negative donor serum/plasma samples. Positive percent agreement (PPA) was 46.15% (95% CI: 19.22% ~74.87%), 61.54% (95% CI: 31.58% ~86.14%), and 97.53% (95% CI: 91.36% ~99.70%) for samples collected on 0-7 days, 8-14 days, and ≥15 days from symptom onset, respectively. Negative Percent Agreement (NPA) was 98.23% (95% CI: 95.53% ~99.52%). No cross-reactivity was observed to patient samples positive for IgG antibodies against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. Conclusion: An anti-SARS-CoV-2 IgG antibody assay with high sensitivity and specificity has been developed. With the high throughput, this assay will speed up the anti-SARS-CoV-2 IgG testing. Citation Format: Jinwei Du, Eric Chu, Dayu Zhang, Chuanyi M. Lu, Aiguo Zhang, Michael Sha. A high-throughput anti-SARS-CoV-2 IgG testing platform for COVID-19 [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2021 Feb 3-5. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(6_Suppl):Abstract nr P22.
Single-cell transcriptomic analyses provide insights into the developmental origins of neuroblastoma
Authors: Selina Jansky, Ashwini Kumar Sharma, Verena Körber, Andrés Quintero, Umut H. Toprak, Elisa M. Wecht, Moritz Gartlgruber, Alessandro Greco, Elad Chomsky, Thomas G. P. Grünewald, Kai-Oliver Henrich, Amos Tanay, Carl Herrmann, Thomas Höfer, Frank Westermann
Journal: Nature Genetics (2021)
P34.06 The Clinical Utility of Liquid Biopsy by Digital Droplet PCR in Patients with Advanced NSCLC
Authors: V. Lamberts, M. Aldea, L. Mezquita, C. Jovelet, D. Vasseur, F. Aboubakar, J. Remon, E. Rouleau, L. Lacroix, M. Ngo Camus, C. Nicotra, C. Naltet, P. Lavaud, A. Gazzah, B. Besse, D. Planchard
Journal: Journal of Thoracic Oncology (2021)
WITHDRAWN: Covid-19: Round and oval areas of ground-glass opacity
Authors: W. Schmitt, E. Marchiori
Journal: Pulmonology (2020)

The Publisher regrets that this article is an accidental duplication of an article that has already been published, DOI of original article: https://doi.org/10.1016/j.pulmoe.2020.04.011 The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Contribution of Polygenic Risk to Hypertension Among Long-Term Survivors of Childhood Cancer
Authors: Yadav Sapkota, Nan Li, Jeanne Pierzynski, Daniel A. Mulrooney, Kirsten K. Ness, Lindsay M. Morton, J. Robert Michael, Jinghui Zhang, Smita Bhatia, Gregory T. Armstrong, Melissa M. Hudson, Leslie L. Robison, Yutaka Yasui
Journal: JACC CardioOncology (2021)

Childhood cancer survivors experience significantly higher rates of hypertension which potentiates cardiovascular disease, but the contribution and relationship of genetic and treatment factors to hypertension risk are unknown.To determine the contribution of a blood pressure polygenic risk score (PRS) from the general population and its interplay with cancer therapies to hypertension in childhood cancer survivors.Using 895 established blood pressure loci from the general population, we calculated a PRS for 3572 childhood cancer survivors of European ancestry from Childhood Cancer Survivor Study (CCSS) original cohort, 1889 from CCSS expansion cohort, and 2534 from the St. Jude Lifetime Cohort (SJLIFE). Hypertension was assessed using National Cancer Institute criteria based on self-report of a physician diagnosis in CCSS and by blood pressure measurement in SJLIFE.In the combined sample of 7995 survivors, those in the top decile of the PRS had an odds ratio (OR) of 2.66 (95% CI=2.03-3.48) for hypertension compared to survivors in the bottom decile. The PRS-hypertension association was modified by being overweight/obese (per SD interaction OR=1.13; 95% CI=1.01-1.27) and exposure to hypothalamic-pituitary axis radiation (per SD interaction OR=1.18; 95% CI=1.05-1.33). Attributable fractions for hypertension to the PRS and cancer therapies were 21.0% and 15.7%, respectively, they jointly accounted for 40.2% of hypertension among survivors.A blood pressure PRS from the general population is significantly associated with hypertension among childhood cancer survivors and contributes to approximately one quarter of hypertension risk among survivors. These findings highlight the importance of screening for hypertension in all childhood cancer survivors, and identify higher risk subgroups.
Human CD141<sup>+</sup> dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model
Authors: Yoke Seng Lee, Liam J O'Brien, Carina M Walpole, Frances E Pearson, Ingrid M Leal-Rojas, Kelly-Anne Masterman, Victoria Atkinson, Andrew Barbour, Kristen J Radford
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background The conventional type 1 dendritic cell subset (cDC1) is indispensable for tumor immune responses and the efficacy of immune checkpoint inhibitor (ICI) therapies in animal models but little is known about the role of the human CD141 + DC cDC1 equivalent in patients with melanoma. Methods We developed a flow cytometry assay to quantify and characterize human blood DC subsets in healthy donors and patients with stage 3 and stage 4 metastatic melanoma. To examine whether harnessing CD141 + DCs could improve responses to ICIs in human melanoma, we developed a humanized mouse model by engrafting immunodeficient NSG-SGM3 mice with human CD34 + hematopoietic stem cells (HSCs) from umbilical cord blood followed by transplantation of a human melanoma cell line and treatment with anti-programmed cell death protein-1 (anti-PD-1). Results Blood CD141 + DC numbers were significantly reduced in patients with stage 4 melanoma compared with healthy controls. Moreover, CD141 + DCs in patients with melanoma were selectively impaired in their ability to upregulate CD83 expression after stimulation with toll-like receptor 3 (TLR3) and TLR7/8 agonists ex vivo. Although DC numbers did not correlate with responses to anti-PD-1 and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) ICIs, their numbers and capacity to upregulate CD83 declined further during treatment in non-responding patients. Treatment with anti-PD-1 was ineffective at controlling tumor growth in humanized mice but efficacy was enhanced by indirectly expanding and activating DCs in vivo with fms -like tyrosine kinase-3 ligand (Flt3L) and a TLR3 agonist. Moreover, intratumoral injections of CD141 + DCs resulted in reduced tumor growth when combined with anti-PD-1 treatment. Conclusions These data illustrate quantitative and qualitative impairments in circulating CD141 + DCs in patients with advanced melanoma and that increasing CD141 + DC number and function is an attractive strategy to enhance immunogenicity and response rates to ICIs.
Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Authors: Christian Daniel Fankhauser, Jan Oldenburg, Peter Albers, Ferran Algaba, Carsten Bokemeyer, Joost L. Boormans, Stefanie Fischer, Karim Fizazi, Hendrik Gremmels, Javier Mayor de Castro, Florian Janisch, Tim Muilwijk, Ricardo Leão, David Nicol, Nicola Nicolai, Torgrim Tandstad, M. Pilar Laguna
Journal: European Urology (2021)
A novel ω-conotoxin Bu8 inhibiting N-type voltage-gated calcium channels displays potent analgesic activity
Authors: Jinqin Chen, Xinhong Liu, Shuo Yu, Jia Liu, Rongfang Chen, Yunxiao Zhang, Ling Jiang, Qiuyun Dai
Journal: Acta Pharmaceutica Sinica B (2021)

ω-Conotoxins inhibit N-type voltage-gated calcium (CaV2.2) channels and exhibit efficacy in attenuating neuropathic pain but have a low therapeutic index. Here, we synthesized and characterized a novel ω-conotoxin, Bu8 from Conus bullatus, which consists of 25 amino acid residues and three disulfide bridges. Bu8 selectively and potently inhibits depolarization-activated Ba2+ currents mediated by rat CaV2.2 expressed in HEK293T cells (IC50 = 89 nmol/L). Bu8 is two-fold more potent than ω-conotoxin MVIIA, a ω-conotoxin currently used for the treatment of severe chronic pain. It also displays potent analgesic activity in animal pain models of hot plate and acetic acid writhing but has fewer side effects on mouse motor function and lower toxicity in goldfish. Its lower side effects may be attributed to its faster binding rate and higher recovery ratios. The NMR structure demonstrates that Bu8 contains a small irregular triple β-strand. The structure–activity relationships of Bu8 Ala mutants and Bu8/MVIIA hybrid mutants demonstrate that the binding mode of CaV2.2 with the amino acid residues in loop 1 and loop 2 of Bu8 is different from that of MVIIA. This study characterizes a novel, more potent ω-conotoxin and provides new insights for designing CaV2.2 antagonists.
MA11.03 Trastuzumab Deruxtecan in HER2-Mutated Metastatic Non-Small Cell Lung Cancer (NSCLC): Interim Results of DESTINY-Lung01
Authors: E. Smit, K. Nakagawa, M. Nagasaka, E. Felip, Y. Goto, B. Li, J. Pacheco, H. Murakami, F. Barlesi, A. Saltos, M. Perol, H. Udagawa, K. Saxena, R. Shiga, F. Guevara, S. Acharyya, J. Shahidi, D. Planchard, P. Jänne
Journal: Journal of Thoracic Oncology (2021)
Response to Comment on Samara et al. Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study. Diabetes Care 2020;43:2691–2701
Authors: Katherine Samaras, John D. Crawford, Brian Draper, Julian N. Trollor, Henry Brodaty, Perminder S. Sachdev
Journal: Diabetes Care (2021)

We thank Violante-Cumpa et al. (1) for their comments on our article that showed metformin use in older people with type 2 diabetes (diabetes) mitigated cognitive decline and incident dementia risk (2). We here respond to each comment.

First, Violante-Cumpa et al. comment that the metformin group took other glucose-lowering medications (50%) compared with 40% in those not on metformin. While metformin is the recommended first line for treatment of diabetes, many people with diabetes …
P39.05 Access Disparities and Challenges in Lung Cancer Diagnostics and Treatment – A European Perspective
Authors: A.M. Baird, D. Villalón, A. Aguarón, C. Smitt-Plank, T. Björk, R. Deniel Ihlen, E. Szmytke, S. Vallone
Journal: Journal of Thoracic Oncology (2021)
PS01.07 Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis
Authors: B. Li, F. Skoulidis, G. Falchook, A. Sacher, V. Velcheti, G. Dy, T. Price, H. Borghaei, M. Schuler, T. Kato, T. Takahashi, A. Spira, S. Ramalingam, B. Besse, F. Barlesi, Q. Tran, H. Henary, G. Ngarmchamnanrith, R. Govindan, J. Wolf
Journal: Journal of Thoracic Oncology (2021)
Abstract 13730: A High BNP Level Precipitates an Improvement in Exercise Tolerance after a Successful Catheter Ablation of Persistent Atrial Fibrillation
Authors: Yoshinori Katsumata, Seiji Takatsuki, Takahiko Nishiyama, Takehiro Kimura, Nobuhiro Nishiyama, Yoko Tanimoto, kojiro Tanimoto, Yoshiyasu Aizawa, keiichi Fukuda
Journal: Circulation (2014)

Introduction:  Atrial fibrillation (AF) has a negative hemodynamic effect that can lead to a decreased exercise tolerance and fatigability on exertion. However, it is unclear whether restoration of sinus rhythm by catheter ablation of AF improves the exercise tolerance. The purpose of this study was to investigate the exercise tolerance quantitatively by comparing that before and after catheter ablation of AF.   Hypothesis:  We assessed the hypothesis that exercise tolerance can improve with sinus rhythm restoration by catheter ablation of persistent AF.   Methods:  This study included 55 consecutive patients who underwent catheter ablation of persistent AF (57.4±1.0 y/o, 51 males, AF duration 2.4±0.3 years). The exercise tolerance determined by cardiopulmonary exercise testing was compared between that prior to, and 3 months after the catheter ablation.   Results:  Sinus rhythm was maintained in 46 patients (84%) over a 3-month follow-up (SR patients), including 20 on oral antiarrhythmic drugs. In the SR patients, the baseline peak oxygen uptake (peak VO 2 ) and VE-VCO 2  slope were 26.2±0.9 ml/kg/min and 27.0±0.6, respectively. The peak VO 2  at 3 months increased significantly (28.6±0.8 ml/kg/min (P 2  decreased significantly (25.9±0.4 ml/kg/min (P 2  in the SR patients exhibited a positive correlation to the baseline BNP (R=0.59 P 2  improved after the AF ablation, the logistic regression analysis revealed the baseline BNP as an independent predictor of a responder (odds ratio 1.032; 95% con[[Unable to Display Character: ﬁ]]dence interval 1.007-1.072; P=0.004).   Conclusions:  The elimination of persistent AF by catheter ablation was associated with an improvement in the exercise tolerance by 3 months after the catheter ablation. This was particularly true in patients with high BNP values at baseline.
Children and the return to school: how much should we worry about covid-19 and long covid?
Authors: Daniel M Altmann
Journal: BMJ (2021)

Among the unknowns that have featured in the steep learning curve of our covid-19 year, the question of risks to (and from) children has been an ongoing area of uncertainty. At first, the conundrum that the young seemed so little affected by the infection prompted at least one world leader to pronounce that they were “somehow immune.”

A year into the pandemic we have a much clearer perspective, especially from random testing surveys such as R, seroprevalence studies, and contact tracing studies. The overwhelming observation has been that, across the pandemic, children and adolescents are considerably less likely to be affected by severe disease or to be admitted to hospital. In transmission tracing studies, children are roughly half as likely as adults to become infected.1 While this is still the case, during the latest wave the age distribution of cases has shifted downwards.

In general, child and adolescent cases account for no more than a few per …
循環器病の診断と治療に関するガイドライン(2006-2007年度合同研究班報告)急性心筋梗塞(ST上昇型)の診療に関するガイドライン
Authors: 高野照夫, 小川聡, 笠貫宏, 木村一雄, 後藤葉一, 住吉徹哉, 代田浩之, 田中啓治, 長尾建, 平山篤志, 幕内晴朗, 山口徹, 山科章, 吉野秀朗, 浅野竜太, 石綿清雄, 大村寛敏, 小菅雅美, 小林俊也, 佐藤俊明, 高木厚, 高山守正, 立花栄三, 寺岡邦彦, 肥後太基, 水野裕八, 安武正弘, 四倉正之, 安達秀雄, 一色高明, 木村剛, 藤原久義, 堀正二
Journal: Circulation (2008)
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Authors: Lari Wenzel, Kathryn Osann, Chelsea McKinney, David Cella, Giulia Fulci, Mary J Scroggins, Heather A Lankes, Victoria Wang, Kenneth P Nephew, George L Maxwell, Samuel C Mok, Thomas P Conrads, Austin Miller, Robert S Mannel, Heidi J Gray, Parviz Hanjani, Warner K Huh, Nick Spirtos, Mario M Leitao, Gretchen Glaser, Sudarshan K Sharma, Alessandro D Santin, Paul Sperduto, Shashikant B Lele, Robert A Burger, Bradley J Monk, Michael Birrer
Journal: JNCI Journal of the National Cancer Institute (2021)

Abstract Background There is a critical need to identify patient characteristics associated with long-term ovarian cancer survival. Methods Quality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared between long-term survivors (LTS) (8+ years) and short-term survivors (STS) (&amp;lt;5 years) of GOG 218 at baseline; before cycles 4, 7, 13, 21; and 6 months post-treatment using linear and longitudinal mixed models adjusted for covariates. Adverse events (AEs) were compared between survivor groups at each assessment using generalized linear models. All P values are 2-sided. Results QOL differed statistically significantly between STS (N = 1115) and LTS (N = 260) (P &amp;lt; .001). Baseline FACT-O-TOI and FACT-O-TOI change were independently associated with long-term survival (odds ratio = 1.05, 95% confidence interval = 1.03 to 1.06 and odds ratio = 1.06, 95% confidence interval = 1.05 to 1.07, respectively). A 7-point increase in baseline QOL was associated with a 38.0% increase in probability of LTS, and a 9-point increase in QOL change was associated with a 67.0% increase in odds for LTS. QOL decreased statistically significantly with increasing AE quartiles (cycle 4 quartiles: 0-5 vs 6-8 vs 9-11 vs ≥12 AEs, P = .01; cycle 21 quartiles: 0-2 vs 3 vs 4-5 vs ≥6 AEs, P = .001). Further, LTS reported statistically significantly better QOL compared with STS (P = .03 and P = .01, cycles 4 and 21, respectively), with similar findings across higher AE grades. Conclusions Baseline and longitudinal QOL change scores distinguished LTS vs STS and are robust prognosticators for long-term survival. Results have trial design and supportive care implications, providing meaningful prognostic value in this understudied population.
Transthoracic shear wave ultrasound: a noninvasive tool to differentiate between benign and malignant subpleural lung lesions
Authors: Johny A. Verschakelen
Journal: European Respiratory Journal (2021)

<b>Measurement of lesion elasticity with transthoracic shear wave ultrasound could be a valuable tool, in addition to CT and grayscale ultrasound, to differentiate between benign and malignant tissue and to guide biopsy of peripheral subpleural lung lesions</b>https://bit.ly/36RjoZV